M Yoshida1, K Muro2, A Tsuji3, Y Hamamoto4, T Yoshino5, K Yoshida6, K Shirao7, Y Miyata8, D Takahari2, T Takahashi6, A Ohtsu5. 1. Cancer Chemotherapy Center, Osaka Medical College Hospital, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan. Electronic address: ctc004@poh.osaka-med.ac.jp. 2. Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan. 3. Department of Medical Oncology, Kochi Health Sciences Hospital, 2125-1 Ike, Kochi 781-8555, Japan. 4. Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, 4-9-13 Yonan, Utsunomiya, Tochigi 320-0834, Japan. 5. Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. 6. Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan. 7. Department of Medical Oncology, Oita University Faculty of Medicine, 1-1, Idaigaoka, Hasamacho, Yufu, Oita 879-5543, Japan. 8. Department of Gastroenterology, Saku Central Hospital, 197 Usuda, Saku, Nagano 384-0393, Japan.
Abstract
BACKGROUND: Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers. METHODS: We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety. RESULTS: From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9months, the median OS was 25.0months, and the RR was 57%. The main adverse events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%). CONCLUSION: Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.
BACKGROUND: Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers. METHODS: We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety. RESULTS: From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9months, the median OS was 25.0months, and the RR was 57%. The main adverse events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%). CONCLUSION: Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.
Authors: Alexander Stein; Julia Quidde; Jan Klaus Schröder; Thomas Göhler; Barbara Tschechne; Annette-Rosel Valdix; Heinz-Gert Höffkes; Silke Schirrmacher-Memmel; Tim Wohlfarth; Axel Hinke; Andreas Engelen; Dirk Arnold Journal: BMC Cancer Date: 2016-02-10 Impact factor: 4.430
Authors: Abdullah Nasser Leslom; Fahad Juwayid Alqahtani; Abdulbari Ahmed Saeed Hanash; Abdullah Abdulhadi Alsubaie; Mohammed Saeed Alamri Journal: J Family Med Prim Care Date: 2020-02-28